Company intelligence / Profile preview
Noile-Immune Biotech Inc.
Minato, Tokyo, Japannoile-immune.com ↗
- Ownership
- Public · 4893
- Employees
- ~25
- Development stage
- Phase 1
01
Overview
Noile‑Immune’s autologous CAR-T cell therapy for solid tumors has shown promising Phase 1 results with no dose-limiting toxicity observed and evidence of anti-tumor activity such as tumor shrinkage in patients with hepatocellular carcinoma. The company recently regained full rights to its lead programs from Takeda and continues clinical development independently.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapies (chimeric antigen receptor T-cell)gene-modified immune cells
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Takeda Pharmaceutical Company Limited (collaboration for next-gen CAR‑T; now returned assets)Adaptimmune Therapeutics plc (co-development using PRIME platform)Takara Bio Inc. (manufacturing partnership for NIB103 in Japan)
Beyond the preview
Go deeper on Noile-Immune Biotech Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Noile-Immune Biotech Inc..